Sign up to save your podcasts
Or
Share What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
View all episodes
By cancerGRACE - H. Jack West, MD"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
More shows like GRACEcast Radiation Oncology Audio
View all
GRACEcast Head and Neck Cancer Audio
2 Listeners
GRACEcast Lung Cancer Video
1 Listeners
GRACEcast Radiation Oncology Video
0 Listeners
GRACEcast Pancreatic Cancer Audio
0 Listeners
GRACEcast Pancreatic Cancer Video
1 Listeners
GRACEcast Cancer 101 Audio
0 Listeners
GRACEcast Bladder Cancer Video
0 Listeners
GRACEcast Head and Neck Cancer Video NEW
0 Listeners
GRACEcast Cancer 101 Video
0 Listeners